European Primary Care Cardiovascular Society

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Improved outcomes with SGLT2i in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Patients with heart failure benefit from SGLT2i regardless of ejection fraction

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Clinical events with low-sodium diet in HF

3' education - Apr. 12, 2022 - Prof. Justin Ezekowitz

Are HF patients harmed when they add salt to their egg?

3' education - Apr. 3, 2022 - Joseph Cleveland, MD

Iron deficiency in HF: Outcomes, pathophysiology and management

10' education - Mar. 7, 2022 - Robert Mentz, MD and prof. Peter van der Meer, MD, PhD

Evaluating the role of a non-steroidal MRA in patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

A pooled analysis of two large HF trials with SGLT2i shows exciting findings

3' education - Oct. 5, 2021 - Milton Packer, MD

The 2021 ESC HF guidelines: What is new regarding patients with EF>40%?

3' education - Sep. 10, 2021 - Prof. Carolyn Lam, MD, PhD

Proven safety with ARNI in MI patients, but no definite difference for primary endpoint

5' education - May 27, 2021 - Prof. Marc Pfeffer, MD, PhD

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Reduced HF hospitalization in patients with iron deficiency after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

ARNI seems to give CV benefit up to EF of about 60%, not only in HFrEF

3' education - Nov. 16, 2019 - Scott Solomon, Boston - AHA 2019, Philadelphia

Does HF have two physiologies that respond differently to treatment, or is it the same disease across the EF spectrum?

3' education - Nov. 18, 2019 - Lynne Stevenson, Nashville - AHA 2019, Philadelphia

SGLT2 inhibitor improves health status in HFrEF

3' education - Nov. 17, 2019 - Mikhail Kosiborod, Kansas City - AHA 2019, Philadelphia
EPCCS Annual CV Summit

Heart failure and comorbidities: kidney disease and cancer

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander

EPCCS

3' education - Feb. 8, 2019

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands

Complexities of managing heart failure

10' education - Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Clare Taylor, Dr. Nuria Farré and Dr. Frans Rutten
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management varies substantially across European countries

10' education - May 25, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague

Low adherence and persistence with HF therapies in newly diagnosed HF patients

Literature - Nov. 29, 2022 - Ødegaard KM, et al. - ESC Heart Fail. 2022

A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.

Improved outcomes with SGLT2i in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD
**ESC 2022** Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.

ESC 2022 Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.

Patients with heart failure benefit from SGLT2i regardless of ejection fraction

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD
Prof. Jhund talks about the findings and implications from a pooled analysis of DAPA-HF and DELIVER with dapagliflozin in of HF patients covering the entire LVEF spectrum.

ESC 2022 Prof. Jhund talks about the findings and implications from a pooled analysis of DAPA-HF and DELIVER with dapagliflozin in HF patients covering the entire LVEF spectrum.

SGLT2i reduces primary endpoint in HFmrEF and HFpEF

News - Aug. 27, 2022

ESC 2022 The DELIVER trial shows that dapagliflozin reduced the risk of CV death or worsening HF in patients with HFmrEF or HFpEF, with no attenuation of treatment benefit in patients with the highest EF.

SGLT2i improves outcomes in heart failure across entire ejection fraction range

News - Aug. 27, 2022

ESC 2022 A pooled analysis of DAPA-HF and DELIVER was undertaken to examine the effect of dapagliflozin in patient with heart failure across the entire spectrum of ejection fraction.

ARNI does not impair cognitive function in HFpEF or HFmrEF

News - Aug. 26, 2022

ESC 2022 The PERSPECTIVE trial showed that sacubitril/valsartan, compared to valsartan, does not impair cognitive function or cause accumulation of amyloid β-peptides in the brain in patients with HFpEF or HFmrEF.

Similar association of smoking and its cessation with HFpEF and HFrEF

Literature - June 15, 2022 - Ding N, et al. - J Am Coll Cardiol. 2022

Smoking is an important modifiable risk factor for HF. But to what extent does this apply to the 2 phenotypes of HF: HFrEF and HFpEF? And what is the effect of (long-term) smoking cessation? A recent analysis of the ARIC study offers valuable insights.

Improved guideline-directed therapy prescription for HFrEF with electronic health record alert

News - Apr. 19, 2022

ACC 2022 This randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.

Novel potassium binder maintains lower K+ levels in HFrEF

News - Apr. 16, 2022

ACC 2022 In the DIAMOND trial, use of patiromer not only resulted in maintenance of lower levels of potassium (K+) compared to placebo, but also in a lower risk of hyperkalemia events and in enablement of RAASi therapy in HFrEF patients on RAASi therapy.

Reduced sodium intake in HF does not lower clinical events

News - Apr. 15, 2022

ACC 2022 Although a reduction in sodium intake in HF patients did not result in a reduction of all-cause mortality of CV hospitalization compared to usual care, patient-centered outcomes were improved.

Potassium binder results in optimization of RAASi and low risk of hyperkalemia in HFrEF

3' education - Apr. 14, 2022 - Prof. Javed Butler, MD
What are the findings of the DIAMOND trial with the potassium binder patiromer in patients with HFrEF who were on RAASi therapy?

ACC 2022 What are the findings of the DIAMOND trial with the potassium binder patiromer in patients with HFrEF who were on RAASi therapy?

Quality of care improved with EHR-based intervention for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD
Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.

ACC 2022 Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.